Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation

被引:55
作者
Colletier, PJ
Ashoori, F
Cowen, D
Meyn, RE
Tofilon, P
Meistrich, ME
Pollack, A
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2000年 / 48卷 / 05期
关键词
prostate cancer; gene therapy; p53; radiotherapy; apoptosis;
D O I
10.1016/S0360-3016(00)01409-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose/Objective: The effect of adenoviral-mediated p53 transgene expression on the radiation response of two human prostate cancer cell lines, the p53(wild-type) LNCaP and p53(null) PC3 lines, was examined. The objective was to determine if this vector sensitizes cells to radiation independently of their p53 status. Methods and Materials: A recombinant adenovirus-5 vector (RPR/INGN 201, Introgen Therapeutics, Houston, TX) containing a CMV promoter and wild-type p53-cDNA (Ad5-p53) was used to facilitate p53 transgene expression. A multiplicity of infection (MOI) of 10-40 viral particles per cell was used, based on Ad5/CMV/lacz infection and staining for the beta -galactosidase reporter gene product. Clonogenic assays were performed to evaluate the degree of sensitization to radiation of viral-transduced cells compared with irradiated nontransduced controls. The relative efficacy of these treatments to induce apoptotic cell death was determined using the TUNEL assay. Results: The delivery of Ad5-p53 (10 MOI) reduced control plating efficiency from 36.5% to 0.86% in the LNCaP cell line and from 75.1% to 4.1% in the PC3 cell line. After correcting for the effect of Ad5-p53 on plating efficiency, the surviving fraction after 2 Gy (SF2) of gamma-irradiation was reduced over 2.5-fold, from 0.187 to 0.072, with transgene p53 expression in the LNCaP cell line. Surviving fraction after 4 Gy (SF4) was reduced over 4.5-fold, from 0.014 to 0.003, after Ad5-p53 treatment. In the PC3 cell line, Ad5-p53 (40 MOI) reduced SF2 over 19-fold from 0.708 to 0.367, and SF4 over 6-fold from 0.335 to 0.056. In both the LNCaP and PC3 cell lines, the combination of Ad5-p53 plus radiation (2 Gy) resulted in supra-additive apoptosis (similar to 20% for LNCaP and similar to 15% for PC3 at 50 MOI), above that seen from the addition of the controls; control vector Ad5-pA plus RT (0.15% for LNCaP and 1.44% for PC3), Ad5-p53 alone (28.6% for LNCaP and 21.7% for PC3), RT alone (0% for LNCaP and 0.23% for PC3), or Ad5-pb alone (0.1% for LNCaP and 0.29% for PC3). Conclusion: The clonogenic survival and apoptosis data demonstrate that p53 transgene expression sensitizes human prostate adenocarcinoma cells in vitro to irradiation. As this effect was observed in both the p53(wild-type) LNCaP and p53(null) PC3 lines, radiosensitization was independent of p53 status. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:1507 / 1512
页数:6
相关论文
共 31 条
  • [1] Combined radiation and p53 gene therapy of malignant glioma cells
    Badie, B
    Goh, CS
    Klaver, J
    Herweijer, H
    Boothman, DA
    [J]. CANCER GENE THERAPY, 1999, 6 (02) : 155 - 162
  • [2] Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
    Bolla, M
    Gonzalez, D
    Warde, P
    Dubois, JB
    Mirimanoff, RO
    Storme, G
    Bernier, J
    Kuten, A
    Sternberg, C
    Gil, T
    Collette, L
    Pierart, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) : 295 - 300
  • [3] COLOMBEL M, 1993, AM J PATHOL, V143, P390
  • [4] RADIATION-INDUCED APOPTOSIS - RELEVANCE TO RADIOTHERAPY
    DEWEY, WC
    LING, CC
    MEYN, RE
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 33 (04): : 781 - 796
  • [5] Gallardo D, 1996, CANCER RES, V56, P4891
  • [6] GOLD R, 1994, LAB INVEST, V71, P219
  • [7] GomezManzano C, 1996, CANCER RES, V56, P694
  • [8] GORCZYCA W, 1993, CANCER RES, V53, P1945
  • [9] Hamada K, 1996, CANCER RES, V56, P3047
  • [10] Harrison G S, 1997, Oncology (Williston Park), V11, P845